Antipsychotic Augmentation vs Monotherapy in Schizophrenia
To augment or not to augment? That is the question.
View the slides in PDF format. Also see: Antipsychotics and Breast Cancer Risk.
Inadequate response to antipsychotic treatment in schizophrenia is common. Scroll through the slides to read about strategies for antipsychotic non-responders and recent studies.
Inadequate response to antipsychotic treatment in schizophrenia is common.[1]
Strategies for antipsychotic non-responders.
Antipsychotic polypharmacy is common.
A study by Galling and colleagues[2] compared the efficacy and adverse effects of antipsychotic augmentation versus monotherapy.
31 studies were included in the meta-analysis.
Antipsychotic augmentation was not superior to monotherapy for total symptom reduction.
Few differences in adverse effects were observed.
This is the first meta-analysis of RCTs focusing exclusively on augmentation strategies...
The authors emphasize that findings should be interpreted with some caution.
